血管内皮细胞生长因子在口腔鳞状细胞癌进展和预后中的作用研究进展

中国口腔颌面外科杂志 ›› 2014, Vol. 12 ›› Issue (2): 175-178.

血管内皮细胞生长因子在口腔鳞状细胞癌进展和预后中的作用研究进展

马海龙, 钟来平, 张志愿

上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,上海市口腔医学重点实验室,上海 200011

收稿日期:2013-07-18 修回日期:2013-08-10 出版日期:2014-03-10 发布日期:2014-11-06
通讯作者: 张志愿,E-mail: zhang.z.y@hotmail.com
作者简介:马海龙(1988-),男,在读硕士研究生,E-mail：mahl21@163.com

Research progress of vascular endothelial growth factor in progression and prognosis of oral squamous cell carcinoma

MA Hai-long, ZHONG Lai-ping, ZHANG Zhi-yuan

Department of Oromaxillofacial Head and Neck Oncology, Ninth People’s Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2013-07-18 Revised:2013-08-10 Online:2014-03-10 Published:2014-11-06

摘要/Abstract

摘要： 血管内皮细胞生长因子(vascular endothelial growth factor, VEGF)是目前被鉴定出的最强的血管生长因子,其家族由7个配体、3种受体以及2种共受体组成。通过多条信号通路,VEGF表现出促进血管内皮细胞增殖和新生血管形成、淋巴内皮细胞生长和淋巴道转移、抗凋亡等多种细胞学效应。肿瘤的生长、转移及预后与VEGF密切相关,新生血管既为肿瘤生长提供营养,也为肿瘤的转移提供通道。本文针对VEGF及其受体的分子结构、信号机制、细胞学效应,以及其与口腔鳞状细胞癌(oral squamous cell carcinoma, OSCC)进展和预后的关系等进行综述。

关键词: 血管内皮细胞生长因子, 口腔鳞状细胞癌, 信号通路

Abstract: Vascular endothelial growth factor (VEGF) has proven to be the most critical angiogenic factor identified to dates, whose family members are composed of 7 ligands, 3 receptors and 2 co-receptors. Through multiple signaling pathways, VEGF shows capacities of promoting vascular endothelial cell proliferation and angiogenesis, lymphatic endothelial cell growth and lymphatic metastasis, and antiapoptotic cell biology effect. Tumor growth, metastasis and prognosis are closely related with VEGF. Newly-born vessels provide nutrition for tumor growth, as well as providing channel for tumor migration. This review focused on the molecular structure of VEGF and its receptors, signal mechanisms, cytology effects, and its relation with progression and prognosis of oral squamous cell carcinoma (OSCC ).

Key words: Vascular endothelial growth factor, Oral squamous cell carcinoma, Signal pathway

中图分类号:

R739.8

马海龙, 钟来平, 张志愿. 血管内皮细胞生长因子在口腔鳞状细胞癌进展和预后中的作用研究进展[J]. 中国口腔颌面外科杂志, 2014, 12(2): 175-178.

MA Hai-long, ZHONG Lai-ping, ZHANG Zhi-yuan. Research progress of vascular endothelial growth factor in progression and prognosis of oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2014, 12(2): 175-178.

参考文献

[1] Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
[2] Yhee JY, Yu CH, Kim JH, et al. Angiogenesis and expression of vascular endothelial growth factor, tumour necrosis factor-α and hypoxia inducible factor-1α in canine renal cell carcinoma [J]. J Comp Pathol, 2012, 147(2-3): 129-138.
[3] Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review [J]. Blood Cells Mol Dis, 2007, 38(3): 258-268.
[4] Ambasta RK, Sharma A, Kumar P. Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy [J]. Vasc Cell, 2011, 3: 26.
[5] Altmann HK, Gertsch J. Anticancer drugs from nature natural products as a unique source of new microtubule-stabilizing agents [J]. Nat Prod Rep, 2007, 24(2): 327-357.
[6] Shen K, Ji L, Gong C, et al. Notoginsenoside Ft1 promotes angiogenesis via HIF-1α mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways[J]. Biochem Pharmacol, 2012, 84(6): 784-792.
[7] Feng Y, Hu J, Ma J, et al. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways[J]. Eur J Cancer, 2011, 47(15): 2353-2363.
[8] Pan R, Dai Y, Gao XH, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways [J]. Vascul Pharmacol, 2011, 54(1-2): 18-28.
[9] Jesmin S, Zaedi S, Islam AM, et al. Time-dependent alterations of VEGF and its signaling molecules in acute lung injury in a rat model of sepsis [J]. Inflammation, 2012, 35(2): 484-500.
[10] van den Akker NM, Caolo V, Molin DG, et al. Cellular decisions in cardiac out ow tract and coronary development: an act by VEGF and NOTCH [J]. Differentiation, 2012, 84(1): 62-78.
[11] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress [J]. Endocr Rev, 2004, 25(4): 581-611.
[12] Miao HQ, Hu K, Jimenez X, et al. Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2 [J]. Biochem Biophys Res Commun, 2006, 345(1): 438-445.
[13] Rius J, Martínez-Gonz&#x0dbc0;&#x0dd61;lez J, Crespo J, et al. NOR-1 is involved in VEGF-induced endothelial cell growth [J]. Atherosclerosis, 2006, 184(2): 276-282.
[14] Bryan BA, Dennstedt E, Mitchell DC, et al. RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis [J]. FASEB J, 2010, 24(9): 3186-3195.
[15] Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis [J]. Proc Natl Acad Sci USA, 2009, 106(15): 6152-6157.
[16] Nayak S, Goel MM, Chandra S, et al. VEGF-A immunohistochemical and mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous cell carcinomas [J]. Oral Oncol, 2012, 48(3): 233-239.
[17] 张从纪,李慧增,周树夏,等.颌面部爆炸伤早期血管内皮生长因子表达的免疫组化分析[J].口腔颌面外科杂志,2000,10(1):20-23.
[18] Liu CJ, Chang KW, Lin SC, et al. Presurgical serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in oral squamous cell carcinoma [J]. Oral Oncol, 2009, 45(10): 920-925.
[19] Seki S, Fujiwara M, Matsuura M, et al. Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors [J]. Oral Oncol, 2011, 47(7): 588-593.
[20] Cheng SJ, Lee JJ, Cheng SL, et al. Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma[J]. Oral Oncol, 2012, 48(5): 424-428.
[21] Cheng SJ, Cheng SL, Lee JJ, et al. Increased placenta growth factor mRNA level is signi cantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma[J]. J Formos Med Assoc, 2013, 112(5): 253-258.
[22] Cheng SL, Lee JJ, Kok SH, et al. Expression of vascular endothelial growth factor is significantly associated with progression and prognosis of oral squamous cell carcinomas in Taiwan [J]. J Formos Med Assoc, 2011, 110(1): 50-57.
[23] Korostoff A, Reder L, Masood R, et al. The role of salivary cytokine biomarkers in tongue cancer invasion and mortality [J]. Oral Oncol, 2011, 47(4): 282-287.
[24] Sweeny L, ZimmermannTM, Liu Z, et al. Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts [J]. Oral Oncol, 2012, 48(12): 1242-1249.
[25] Park SJ, Kim MJ, Kim YK, et al. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma [J]. Cancer Lett, 2010, 292(1): 54-63.
[26] 郭伟. 晚期口腔颌面头颈部鳞癌靶向治疗的进展浅析 [J]. 口腔颌面外科杂志, 2012, 22(2): 77-81.